



# APPENDIX 4C

Quarter Ended 31 March 2026

**Chimeric Therapeutics Limited**

ACN 638 835 828

**ASX: CHM**



ASX ANNOUNCEMENT

29 APRIL 2026

## QUARTERLY ACTIVITIES REPORT FOR THE PERIOD ENDING 31 MARCH 2026

**Sydney, Australia, 29 April 2026:** Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, is pleased to provide a summary of its activities for the quarter ended 31 March 2026.

- CHM CDH17 advances to Dose Level 3 of 450 million CDH17 CART+ cells, with Dose Levels 1 and 2 were completed with no safety or off target effects observed
- CHM CDH17 CART+ cells have been detected in the blood for more than 12 months, indicating exceptional persistence
- Subsequent to the end of the quarter, CHM CORE-NK Phase 1b clinical trial achieves 60% CR/CRI from 25 patients enrolled (15 out of 25)
- Portfolio streamlined with return of CHM CLTX to City of Hope, reinforcing focus on CHM CDH17 program as part of strategic reset
- Experienced biotechnology & cell therapy specialist Dr Bradley Glover appointed Non-Executive Chair as part of Board refresh
- Mr Aaron Laurita appointed Chief Financial Officer, bringing strong financial and commercial expertise to Chimeric

### Clinical Trial Updates

#### **CHM CDH17 Advances to Dose Level 3**

In February, the Company announced that the CHM CDH17 trial has advanced to Dose Level 3 of 450 million CDH17 CART+ cells. Dose Levels 1 and 2 in clinical trial subjects provided early signs of activity and a compelling safety profile, with no safety concerns or off target effects observed. Eleven successful manufacturing runs have now been completed.

One Colorectal Cancer (CRC) patient has experienced stable disease for 13 months from a single dose at Dose Level 1. Another CRC patient has experienced stable disease that is ongoing at 9 months from a single dose at Dose Level 2. Both patients are continuing on study and have not required any other therapies throughout this time. All subjects have demonstrated expansion and persistence of the CHM CDH17 CART+ cells for up to 12 months to date.

The clinical expansion observed, coupled with no evidence of off-tumour effects or gastrointestinal toxicity, significantly de-risks CHM CDH17.

The Phase 1 portion of this study is expected to enrol up to 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts.



### **CHM CORE-NK Phase 1b clinical trial achieves 60% CR/CRi**

Following the reporting period, Chimeric announced new clinical data from the ADVENT-AML NCT05834244 clinical trial, with 60% of 25 patients enrolled (15 out of 25) achieving a CR/CRi (Complete Response/Complete response incomplete count recovery).

The frontline cohort continues to enrol high risk AML patients, ineligible for stem cell transplant, at The University of Texas MD Anderson Cancer Center. There have been no unexpected safety findings in this group of patients and the combination of CHM CORE-NK with azacitidine and venetoclax continues to be well-tolerated by patients.

Durability of response continues to be assessed by Chimeric's partners at MD Anderson. Translational data, such as persistence and cytokine profiles, are currently being evaluated.

The ADVENT-AML (NCT05834244) Phase 1B clinical trial is an investigator-initiated study currently open to enrollment at MD Anderson Cancer Center under Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia. Investigator-initiated trials are clinical research studies conceived, designed, and managed by independent researchers (clinicians/academics) rather than biotechnology companies. This study is evaluating the synergy of NK cell therapy in combination with the current standard of care, Azacitidine and Venetoclax.

### **Portfolio Streamlined with Return of CHM CLTX to City of Hope**

Chimeric entered into an arrangement to return to City of Hope the Chlorotoxin (CHM CLTX) CAR T-cell therapy asset that it exclusively licensed in 2020. City of Hope will assume full ownership and control of the CHM CLTX intellectual property and associated program. Since in-licensing the CHM CLTX program, Chimeric has advanced and expanded its broader pipeline, with the Board and Management determining that discontinuing its development of CHM CLTX asset represents a disciplined capital management decision that aligns with the Company's focus on advancing its core program.

## **Corporate Updates**

### **Board and Management Team Changes**

As part of the Company's Board of Directors refresh announced on 28 November 2025, Chimeric announced the appointment of Dr Bradley Glover as Non-Executive Director and Chair following a global recruitment process.

Dr Glover is an accomplished biotechnology executive with over 20 years of leadership experience across global biopharmaceuticals, cell therapy, biomaterials, and life sciences, spanning both public and private companies. He brings deep expertise in cell and gene therapy, corporate development, and capital formation, with a strong track record of executing value-creating strategic transactions, while leading organisations through critical clinical, operational and commercial inflection points.



With Dr Glover's appointment, Acting Chair Mr Phillip Hains will continue to serve as a Non-Executive Director, and has stepped down from his role as Joint Company Secretary and Chief Financial Officer.

The Company also appointed Mr Aaron Laurita as Chief Financial Officer. Mr Laurita brings strong finance and commercial expertise to Chimeric, developed through working with organisations across several sectors, including the biotechnology sector, in Australia, the United States and Canada over the past decade.

### **NWR Virtual Healthcare Conference**

In March, CEO Dr Rebecca McQualter presented at the NWR Virtual Healthcare Conference, where she provided an update on the Company's activities.

A replay of the presentation is available at: <https://youtu.be/CxOg6sU7nKM?si=2jzJa-Bv-W3p6O4>

### **Financial Updates**

An Appendix 4C Quarterly Cash Flow report is attached to this announcement.

As detailed in the attached ASX Appendix 4C the Company had \$1.75 million in cash and cash equivalents at 31 March 2026, decreasing from \$2.50 million at the end of the prior quarter.

The net cash outflow in Operating Activities during the quarter was \$3.42 million with 90% of operating activities relates to staff costs and research and development as detailed in the Appendix 4C.

The net financing inflows for the quarter was \$2.68 million which consists of \$0.93 million received as part of the December Placement and \$1.79 million from entering into an advance on the Company's anticipated FY26 Research and Development Tax Incentive (RDTI).

### **Funding and EGM Update**

In February, the Company provided an update to the \$8.4 million funding announced to the ASX on 23 December 2025:

The funding comprises:

- A \$4.4 million (before costs) placement to institutional, sophisticated and professional investors (**Placement**) in two tranches:
  - **Tranche 1:** approximately 777 million shares (~\$2.3 million) issued under the Company's existing placement capacity on 31 December 2025 and 7 January 2026; and
  - **Tranche 2:** approximately 690 million shares (~\$2.1 million), including the ~1.5 billion attaching options for Tranches 1 and 2, subject to shareholder approval to be sought at an extraordinary general meeting (EGM);
  - The Placement includes US\$2.0 million (approximately ~A\$2.8 million) committed by a US-based family office.



- A\$4.0 million (before costs) Convertible Note and associated Warrants committed by a second US institutional investor committing, to settle with Tranche 2, subject to shareholder approval.

The Notice of Extraordinary General Meeting (EGM) incorporating all relevant details for approval of Tranche 2 shares, placement options and the convertible note and associated warrants, (including an Independent Expert Report relating to the family office investment), was submitted to the ASX on 19 March 2026, in accordance with the Listing Rules, and was held on 17 April 2026.

### **Chimeric receives \$1.8 M advance on FY26 R&D tax incentive**

The Company has received \$1,785,000 from Radium Capital under a funding facility secured against Chimeric's anticipated FY26 Research and Development Tax Incentive (RDTI) to be received from the Australia Tax Office. Repayment is timed to follow the anticipated receipt of the Company's FY26 RDTI, due by 31 December 2026. The facility can be repaid at any time without penalty prior to this date, subject to a minimum interest period of 90 days.

The funds will support the clinical trial pipeline and otherwise for general working capital of the Company.

### **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics Board of Directors.



**Contact**

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: [investors@chimerictherapeutics.com](mailto:investors@chimerictherapeutics.com)

W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Chimeric Therapeutics Limited

**ABN**

68 638 835 828

**Quarter ended ("current quarter")**

31 March 2026

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (9 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers (inclusive of GST)	-	-
1.2 Payments for (inclusive of GST)		
(a) research and development	(2,511)	(7,434)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs*	(578)	(2,919)
(f) administration and corporate costs	(382)	(1,502)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	8	36
1.5 Interest and other costs of finance paid	-	(107)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	4,498
1.8 Other (provide details if material)	48	174
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(3,415)</b>	<b>(7,254)</b>

\*Staff costs includes staff, directors, scientific advisors and employment related costs.

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (Payments of license fee liabilities)	-	(249)
<b>2.6 Net cash from / (used in) investing activities</b>	<b>-</b>	<b>(249)</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	930	6,707
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	(35)	(628)
3.5 Proceeds from borrowings	1,785	1,785
3.6 Repayment of borrowings	-	(2,500)
3.7 Transaction costs related to loans and borrowings	-	(185)
3.8 Dividends paid	-	-
3.9 Other – repayment of debt facility	-	(1,665)
<b>3.10 Net cash from / (used in) financing activities</b>	<b>2,680</b>	<b>3,514</b>

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (9 months) \$A'000</b>
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	2,504	5,757
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,415)	(7,254)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(249)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,680	3,514
4.5	Effect of movement in exchange rates on cash held	(19)	(18)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>1,750</b>	<b>1,750</b>

<b>5. Reconciliation of cash and cash equivalents</b>	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		
5.1 Bank balances	1,750	2,504
5.2 Call deposits	-	-
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
<b>5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>1,750</b>	<b>2,504</b>

<b>6. Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1 Aggregate amount of payments to related parties and their associates included in item 1	50
6.2 Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>	

Item 6.1 – Include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

<b>7. Financing facilities</b>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 <b>Total financing facilities</b>	-	-
7.5 <b>Unused financing facilities available at quarter end</b>		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

<b>8. Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(3,415)
8.2 Cash and cash equivalents at quarter end (item 4.6)	1,750
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	<b>1,750</b>
8.5 <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	0.51
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
<p>Answer:</p> <p>The Company does not expect to continue to have a similar level of net operating cash flows and will continue to reduce its discretionary operational activities to preserve available cash.</p>	

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

The Board continues to assess alternative sources of capital to fund the Company's ongoing operations. The Directors believe the Company can raise sufficient capital through a combination of equity financing and/or non-dilutive funding sources.

This is further supported by the announcement released on 25 February 2026, the Company announced that they had raised \$4.4 million as part of a placement with \$2.1 million to be received this month after being approved by shareholders at the EGM on 17 April.

In addition, the Company announced commitment of \$4 million (before costs) in a convertible noted and associated warrants the Company can drawn down. This was also approved by shareholders at the EGM on 17 April.

In addition, the Company has implemented, and will continue to implement, cash management measures, including the deferral of discretionary operational activities, to preserve available cash.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Yes, the Board expects to be able to continue its operations and to meet its business objectives based on the responses detailed in 8.6.1 and 8.6.2.

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 29 April 2026

Authorised by: The Board  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.



**CHIMERIC**  
THERAPEUTICS

☎ +61 3 9824 5254

✉ [info@chimerictherapeutics.com](mailto:info@chimerictherapeutics.com)

**Chimeric Therapeutics Limited**

ACN 638 835 828

**ASX: CHM**